BACKGROUND: Immune activation and exhaustion drive several comorbidities and disease progression in HIV-infected adults; however, they are not well studied in HIV-infected youth. Thus, this study sought to examine levels of immune activation and exhaustion in this population, investigate associated HIV- and non-HIV-related variables and compare results with a matched healthy control group. METHODS: HIV-infected youth 8-25 years of age on stable antiretroviral therapy with an HIV-1 RNA level <1000 copies/mL were enrolled, along with matched healthy controls. We measured T-cell and monocyte immune activation and exhaustion markers in cryopreserved peripheral blood mononuclear cell and plasma samples. RESULTS: A total of 136 subjects (80 HIV+: 66% male; 91% black) were enrolled. Markers of CD4+ and CD8+ T-cell activation were higher in the HIV-infected group versus controls [mean % CD4+CD38+HLA-DR+ and CD8+CD38+HLA-DR+ = 2.2 versus 1.5 (P=0.002) and 4.9 versus 2.2 (P<0.0001), respectively], as were exhausted CD4+ and CD8+ T-cells [mean % CD4+CD38+HLA-DR+PD-1+ and CD8+CD38+HLA-DR+PD-1+ = 1.0 versus 0.5 (P<0.0001) and 1.6 versus 0.7 (P<0.0001), respectively]. There were no differences in proportions of inflammatory or patrolling monocytes between groups (P>0.05); however, soluble CD14 was higher in HIV-infected compared with controls (1.6 versus 1.4 µg/mL; P=0.01). Current CD4 count, low-density lipoprotein cholesterol and age were the variables most associated with CD4+ and CD8+ T-cell activation. CONCLUSIONS: CD4+ and CD8+ T-cell immune activation and exhaustion are higher in HIV-infected youth compared with matched controls, while monocyte subpopulations are not altered despite a high soluble CD14 level. The clinical significance of the increased immune activation and exhaustion should be further explored.
BACKGROUND: Immune activation and exhaustion drive several comorbidities and disease progression in HIV-infected adults; however, they are not well studied in HIV-infected youth. Thus, this study sought to examine levels of immune activation and exhaustion in this population, investigate associated HIV- and non-HIV-related variables and compare results with a matched healthy control group. METHODS:HIV-infected youth 8-25 years of age on stable antiretroviral therapy with an HIV-1 RNA level <1000 copies/mL were enrolled, along with matched healthy controls. We measured T-cell and monocyte immune activation and exhaustion markers in cryopreserved peripheral blood mononuclear cell and plasma samples. RESULTS: A total of 136 subjects (80 HIV+: 66% male; 91% black) were enrolled. Markers of CD4+ and CD8+ T-cell activation were higher in the HIV-infected group versus controls [mean % CD4+CD38+HLA-DR+ and CD8+CD38+HLA-DR+ = 2.2 versus 1.5 (P=0.002) and 4.9 versus 2.2 (P<0.0001), respectively], as were exhausted CD4+ and CD8+ T-cells [mean % CD4+CD38+HLA-DR+PD-1+ and CD8+CD38+HLA-DR+PD-1+ = 1.0 versus 0.5 (P<0.0001) and 1.6 versus 0.7 (P<0.0001), respectively]. There were no differences in proportions of inflammatory or patrolling monocytes between groups (P>0.05); however, soluble CD14 was higher in HIV-infected compared with controls (1.6 versus 1.4 µg/mL; P=0.01). Current CD4 count, low-density lipoprotein cholesterol and age were the variables most associated with CD4+ and CD8+ T-cell activation. CONCLUSIONS:CD4+ and CD8+ T-cell immune activation and exhaustion are higher in HIV-infected youth compared with matched controls, while monocyte subpopulations are not altered despite a high soluble CD14 level. The clinical significance of the increased immune activation and exhaustion should be further explored.
Authors: Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek Journal: J Infect Dis Date: 2011-01-20 Impact factor: 5.226
Authors: Juliana Ribeiro Romeiro; Jorge Andrade Pinto; Maria Luiza Silva; Silvana Maria Eloi-Santos Journal: J Int Assoc Physicians AIDS Care (Chic) Date: 2011-10-05
Authors: Adriana Weinberg; Mark J Giganti; Patricia A Sirois; Grace Montepiedra; Jennifer Canniff; Allison Agwu; Michael J Boivin; Suad Kapetanovic; Mark J Abzug Journal: AIDS Date: 2022-04-19 Impact factor: 4.632
Authors: Allison Ross Eckard; Mary Ann O'Riordan; Julia C Rosebush; Seungeun Thera Lee; Jakob G Habib; Joshua H Ruff; Danielle Labbato; Julie E Daniels; Monika Uribe-Leitz; Vin Tangpricha; Ann Chahroudi; Grace A McComsey Journal: Antivir Ther Date: 2018
Authors: Stefano Rinaldi; Suresh Pallikkuth; Mark Cameron; Lesley R de Armas; Nicola Cotugno; Vinh Dinh; Rajendra Pahwa; Brian Richardson; Shelly R Saini; Salvatore Rocca; Maria G Lain; Sion L Williams; Paolo Palma; Savita Pahwa Journal: J Immunol Date: 2019-12-30 Impact factor: 5.422
Authors: Allison Ross Eckard; Paolo Raggi; Mary Ann O'Riordan; Julia C Rosebush; Danielle Labbato; Ann Chahroudi; Joshua H Ruff; Christopher T Longenecker; Vin Tangpricha; Grace A McComsey Journal: Virulence Date: 2017-10-05 Impact factor: 5.882
Authors: Helen Payne; Man K Chan; Sarah A Watters; Kennedy Otwombe; Nei-Yuan Hsiao; Abdel Babiker; Avy Violari; Mark F Cotton; Diana M Gibb; Nigel J Klein Journal: AIDS Res Ther Date: 2021-09-29 Impact factor: 2.250